ENTX Insider Trading (Entera Bio)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $63,815.68
Insider Selling (Last 12 Months): $0.00
Entera Bio Share Price & Price History
Current Price: $1.33
Price Change: ▼ Price Decrease of -0.01 (-0.75%)
As of 06/30/2022 01:00 AM ET
27 U.S. Cities Where Stocks Yield 26% a Year
From Investing Daily | Ad
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.
Entera Bio Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/19/2022 | Ramesh Ratan | CFO | Buy | 10,000 | $2.44 | $24,400.00 | |  |
| 1/18/2022 | Ron Mayron | Director | Buy | 7,000 | $2.80 | $19,600.00 | | |
| 1/13/2022 | Yonatan Malca | Director | Buy | 7,232 | $2.74 | $19,815.68 | | |
Former Lawyer Went From $50K To $5.3M Trading Options
From Investing Daily | Ad
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable.
I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually).
I grew my $50K into $5.3M
I'll show you how I did it here.
Entera Bio Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/12/2022 | PNC Financial Services Group Inc. | 10,000 | $29K | 0.0% | N/A | 0.042% |  |
| 1/31/2022 | Altium Wealth Management LLC | 11,830 | $33K | 0.0% | N/A | 0.050% | |
| 1/28/2022 | ARK Investment Management LLC | 690,922 | $1.95M | 0.0% | +1.2% | 2.915% | |
| 8/17/2021 | Knoll Capital Management LLC | 2,484,275 | $14.86M | 7.8% | +38.7% | 10.482% | |
| 8/16/2021 | RA Capital Management L.P. | 2,353,000 | $14.07M | 0.2% | N/A | 9.928% | |
| 8/13/2021 | Geode Capital Management LLC | 17,597 | $0.11M | 0.0% | N/A | 0.074% | |
| 8/11/2021 | Susquehanna Fundamental Investments LLC | 14,400 | $86K | 0.0% | N/A | 0.061% | |
| 6/14/2021 | Knoll Capital Management LLC | 1,791,363 | $6.83M | 4.4% | +2.9% | 7.558% | |
| 5/18/2021 | Millennium Management LLC | 38,611 | $0.15M | 0.0% | N/A | 0.163% | |
| 5/14/2021 | XTX Topco Ltd | 11,559 | $44K | 0.0% | N/A | 0.101% | |
| 5/13/2021 | Renaissance Technologies LLC | 120,407 | $0.46M | 0.0% | +66.8% | 1.053% | |
| 2/24/2021 | Virtu Financial LLC | 31,314 | $34K | 0.0% | N/A | 0.274% | |
| 2/10/2021 | Renaissance Technologies LLC | 72,186 | $78K | 0.0% | N/A | 0.632% | |
| 10/20/2020 | Wedbush Securities Inc. | 121,616 | $0.15M | 0.0% | +305.3% | 1.064% | |
| 8/10/2020 | Phoenix Holdings Ltd. | 37,400 | $66K | 0.0% | -46.1% | 0.000% | |
| 7/16/2020 | Wedbush Securities Inc. | 30,008 | $55K | 0.0% | N/A | 0.000% | |
| 5/20/2020 | Phoenix Holdings Ltd. | 69,355 | $0.14M | 0.0% | N/A | 0.607% | |
| 2/14/2020 | Wildcat Capital Management LLC | 179,526 | $0.38M | 0.1% | -7.1% | 1.571% | |
| 2/14/2020 | Knoll Capital Management LP | 1,741,363 | $3.61M | 2.7% | +266.2% | 15.238% | |
| 11/27/2019 | Wildcat Capital Management LLC | 193,190 | $0.48M | 0.2% | -4.9% | 1.690% | |
| 8/14/2019 | DLD Asset Management LP | 369,442 | $1.27M | 0.1% | +11.3% | 3.233% | |
| 5/8/2019 | LLBH Private Wealth Management LLC | 60,060 | $0.25M | 0.1% | N/A | 0.525% | |
| 2/15/2019 | Worth Venture Partners LLC | 26,947 | $53K | 0.0% | +113.7% | 0.236% | |
| 1/22/2019 | FNY Investment Advisers LLC | 15,189 | $46K | 0.0% | N/A | 0.133% | |
| 11/13/2018 | DLD Asset Management LP | 280,112 | $1.63M | 0.1% | +12.7% | 2.451% | |
Data available starting January 2016
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Read More on Entera Bio
Volume
38,320 shs
Average Volume
69,054 shs
Market Capitalization
$31.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.65
Who are the company insiders with the largest holdings of Entera Bio?
